|
|
|
Dynavax Reports Third Quarter 2013 Financial Results November 7, 2013 Dynavax Prices Public Offerings of Common Stock and Series B Convertible Preferred Stock October 25, 2013 Dynavax Announces Proposed Public Offerings of Common Stock and Series B Convertible Preferred Stock October 24, 2013 Dynavax Reports on HEPLISAV(TM) Regulatory Path October 16, 2013 Dynavax Initiates First Human Trial in Asthma Program October 9, 2013 September 24, 2013 Dynavax Reports Second Quarter 2013 Financial Results July 29, 2013 |
Our clinical-stage pipeline includes product candidates for the prevention and treatment of infectious diseases. More...
|
Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.
Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.
Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product, HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
|
 |
